Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about FibroGen, Inc.
FibroGen, Inc. News
FibroGen, Inc. Quantitative Score
About FibroGen, Inc.
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. It is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase III trial for the treatment of Duchenne muscular dystrophy. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
FibroGen, Inc. Earnings & Revenue
FibroGen, Inc. Financials
Table Compare
Compare FGEN metrics with: | |||
|---|---|---|---|
Earnings & Growth | FGEN | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | FGEN | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | FGEN | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | FGEN | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
FibroGen, Inc. Income
FibroGen, Inc. Balance Sheet
FibroGen, Inc. Cash Flow
FibroGen, Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Buy |
| Return on Equity | Strong Buy |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Strong Sell |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
FibroGen, Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
FibroGen, Inc. Executives
| Name | Role |
|---|---|
| Mr. Thane Wettig | Chief Executive Officer & Director |
| Mr. Julian N. Stern | Secretary |
| Mr. David DeLucia | Chief Financial Officer |
| Mr. John Alden | General Counsel |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Thane Wettig | Chief Executive Officer & Director | Male | 1965 | 941.8K |
| Mr. Julian N. Stern | Secretary | Male | 1925 | 27.13K |
| Mr. David DeLucia | Chief Financial Officer | Male | -- | |
| Mr. John Alden | General Counsel | Male | -- |
FibroGen, Inc. Insider Trades
| Date | 24 Mar |
| Name | Wettig Thane |
| Role | CEO |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 145000 |
| Date | 20 Mar |
| Name | Schoeneck James A |
| Role | Director |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 250000 |
| Date | 21 Mar |
| Name | Schoeneck James A |
| Role | Director |
| Transaction | Acquired |
| Type | P-Purchase |
| Shares | 50000 |
| Date | 6 Mar |
| Name | Wettig Thane |
| Role | CEO |
| Transaction | Disposed |
| Type | F-InKind |
| Shares | 22038 |
| Date | 6 Mar |
| Name | Wettig Thane |
| Role | CEO |
| Transaction | Acquired |
| Type | A-Award |
| Shares | 781 |
| Date | Name | Role | Transaction | Type | Shares |
|---|---|---|---|---|---|
| 24 Mar | Wettig Thane | CEO | Acquired | P-Purchase | 145000 |
| 20 Mar | Schoeneck James A | Director | Acquired | P-Purchase | 250000 |
| 21 Mar | Schoeneck James A | Director | Acquired | P-Purchase | 50000 |
| 6 Mar | Wettig Thane | CEO | Disposed | F-InKind | 22038 |
| 6 Mar | Wettig Thane | CEO | Acquired | A-Award | 781 |